Christopher M Bunce

List of Publications by Year in Descending Order

44 papers	1,387 citations	18 h-index	37 g-index
45 ext. papers	1,530 ext. citations	4.2 avg, IF	3.59 L-index

#	Paper	IF	Citations
44	Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers. *Contemporary Clinical Trials Communications*, **2019**, 14, 100361	1.8	4
43	The Role of Eif6 in Skeletal Muscle Homeostasis Revealed by Endurance Training Co-expression Networks. *Cell Reports*, **2017**, 21, 1507-1520	10.6	14
42	Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. *Journal of Steroid Biochemistry and Molecular Biology*, **2016**, 155, 47-55	5.1	11
41	Malonate as a ROS product is associated with pyruvate carboxylase activity in acute myeloid leukaemia cells. *Cancer & Metabolism*, **2016**, 4, 15	5.4	14
40	Tracer-Based Metabolic NMR-Based Flux Analysis in a Leukaemia Cell Line. *ChemPlusChem*, **2016**, 81, 453-459	2.8	12
39	The case for extracellular Nm23-H1 as a driver of acute myeloid leukaemia (AML) progression. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2015**, 388, 225-33	3.4	7
38	Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas. *Leukemia and Lymphoma*, **2015**, 56, 1079-87	1.9	3
37	Metabolic Fluxes in Cancer Metabolism **2015**, 315-348		4
36	Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497). *British Journal of Haematology*, **2014**, 164, 888-90	4.5	11
35	Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease. *PLoS ONE*, **2013**, 8, e56422	3.7	32
34	The haematopoietic stem cell niche: new insights into the mechanisms regulating haematopoietic stem cell behaviour. *Stem Cells International*, **2011**, 2011, 274564	5	28
33	Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation. *ACS Chemical Biology*, **2011**, 6, 169-75	4.9	26
32	Nm23-h1 indirectly promotes the survival of acute myeloid leukemia blast cells by binding to more mature components of the leukemic clone. *Cancer Research*, **2011**, 71, 1177-86	10.1	16
31	Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. *Carcinogenesis*, **2010**, 31, 1650-60	4.6	49
30	Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. *PLoS ONE*, **2009**, 4, e4251	3.7	90
29	Analysis of the role of COP9 Signalosome (CSN) subunits in K562; the first link between CSN and autophagy. *BMC Cell Biology*, **2009**, 10, 31		16
28	Where now in elderly AML?. *British Journal of Haematology*, **2009**, 145, 333	4.5	1

27	Characterization of two novel aldo-keto reductases from Arabidopsis: expression patterns, broad substrate specificity, and an open active-site structure suggest a role in toxicant metabolism following stress. *Journal of Molecular Biology*, **2009**, 392, 465-80	6.5	101
26	Evaluation of solvent accessibility epitopes for different dehydrogenase inhibitors. *ChemMedChem*, **2008**, 3, 1371-6	3.7	14
25	Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. *Analytical Biochemistry*, **2008**, 377, 16-23	3.1	144
24	The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. *FASEB Journal*, **2005**, 19, 1187-9	0.9	69
23	PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. *Blood*, **2005**, 106, 1362-8	2.2	117
22	All-trans retinoic acid increases transgene expression in MSCV-transduced cells, via a mechanism that is retinoid receptor dependent but independent of cellular differentiation. *Human Gene Therapy*, **2005**, 16, 132-8	4.8	
21	Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. *Cancer Research*, **2004**, 64, 1802-10	10.1	98
20	Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. *Blood*, **2003**, 101, 3212-9	2.2	131
19	The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. *Cancer Research*, **2003**, 63, 505-12	10.1	106
18	Estrone potentiates myeloid cell differentiation: a role for 17 beta-hydroxysteroid dehydrogenase in modulating hemopoiesis. *Experimental Hematology*, **1999**, 27, 451-60	3.1	22
17	Bistratene A induces a microtubule-dependent block in cytokinesis and altered stathmin expression in HL60 cells. *Biochemical and Biophysical Research Communications*, **1999**, 260, 80-8	3.4	13
16	Triiodothyronine blocks potentiation of HL60 monocyte differentiation by anti-inflammatory agents and by steroids and induces apoptosis of all-trans retinoic acid "primed" cells. *Leukemia Research*, **1997**, 21, 623-34	2.7	5
15	Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1996**, 1311, 189-98	4.9	38
14	Growth of single HL60 cells in liquid culture: analysis of the influences of differentiative agents. *Leukemia Research*, **1996**, 20, 821-9	2.7	7
13	Expression of a nuclear envelope protein recognized by the monoclonal antibody BU31 in lung tumours: relationship to Ki-67 antigen expression. *Journal of Pathology*, **1994**, 173, 89-96	9.4	5
12	Intracellular concentrations of inositol, glycerophosphoinositol and inositol pentakisphosphate increase during haemopoietic cell differentiation. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1994**, 1222, 101-8	4.9	30
11	1 alpha,25-Dihydroxyvitamin D3 promotes monocytopoiesis and suppresses granulocytopoiesis in cultures of normal human myeloid blast cells. *Journal of Leukocyte Biology*, **1994**, 56, 124-32	6.5	14
10	Inositol lipids and phosphates in the proliferation and differentiation of lymphocytes and myeloid cells. *Novartis Foundation Symposium*, **1992**, 164, 2-11; discussion 12-6		3

9	Protein phosphorylation events and changes in inositol metabolism during HL60 cell differentiation. *Biochemical Society Transactions*, **1991**, 19, 315-20	5.1	3
8	Changes in inositol transport during DMSO-induced differentiation of HL60 cells towards neutrophils. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1991**, 1091, 158-64	4.9	10
7	Models of haemopoiesis. *Leukemia Research*, **1990**, 14, 495-9	2.7	7
6	Phorbol myristate acetate treatment of normal human myeloid blast cells promotes monopoiesis and inhibits granulopoiesis. *Leukemia Research*, **1990**, 14, 1007-17	2.7	7
5	The development of cell lineages: a sequential model. *Differentiation*, **1988**, 39, 83-9	3.5	27
4	A rapid procedure for isolating hemopoietic cell nuclei. *Analytical Biochemistry*, **1988**, 175, 67-73	3.1	42
3	Expression of a 215,000-dalton nuclear envelope protein decreases during cell maturation. *Leukemia Research*, **1986**, 10, 1175-82	2.7	1
2	Cathepsin B synthesis by the HL60 promyelocytic cell line: effects of stimulating agents and anti-inflammatory compounds. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1986**, 887, 283-90	4.9	11
1	Variant cell lines from the human promyelocyte line HL60. *Leukemia Research*, **1982**, 6, 491-8	2.7	24